Europeanhhm

Viz.ai Teams Up with the Hypertrophic Cardiomyopathy Association to Enhance Patient Care

Saturday, June 15, 2024

Viz.ai has partnered with the Hypertrophic Cardiomyopathy Association (HCMA) to advance support, education, and research for hypertrophic cardiomyopathy (HCM).

HCM is the most common inherited cardiovascular disease and a leading cause of sudden cardiac death in young adults in the U.S., affecting approximately one million people, with only 20% diagnosed.

The condition thickens heart muscles, impeding blood pumping and increasing risks like atrial fibrillation and heart failure.

HCMA CEO Lisa Salberg expressed appreciation for the collaboration, noting its potential to enhance patient support and education. Emphasized the need to identify undiagnosed or misdiagnosed individuals promptly to provide timely access to life-improving treatments.

Viz.ai has developed a machine learning algorithm cleared by regulators to detect early signs of HCM from routine ECGs.

This innovation aims to significantly shorten diagnosis times, potentially reducing the process from symptom onset to confirmation to just 90 days. Viz.ai also launched the HCM Education Series, featuring webinars led by experts and patient advocates to increase awareness and understanding of the disease.

Highlighted their shared goal with HCMA to improve patient care by addressing diagnostic challenges and minimizing the lengthy diagnostic journey associated with HCM.

The collaboration aims to enable earlier disease detection, leading to improved quality of life and better risk management for patients with HCM.







Source: businesswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress